Diabetes
Diabetes worsens Hearing Women
Diabetes can cause women to have a hearing loss is worse with the increase in the age. This disorder is more striking if a metabolic disorder that occurs is not well controlled by medication and diet.
Women aged 60-75 years with diabetes who receive regular care have better hearing than women with poorly controlled diabetes. Women with diabetes who controlled it even has a level of hearing the same with women without diabetes at the same age.
This study also suggests that all women with diabetes aged 60 years and under have a poor level of hearing, even when diabetes is controlled. For men, hearing deterioration experienced by all study participants, regardless of age or whether they had diabetes or not.
Research to be presented at the annual meeting titled Triological Society’s Combined Sections Meeting highlighted the importance of controlling diabetes because of the impact that may occur in hearing, especially with age.
According to the American Diabetes Association, nearly 26 million people in the U.S. have diabetes, and 34.5 million people have hearing loss. Signs of hearing loss include difficulty hearing the background noise or hear conversations in large groups, and often vary the volume of radio or TV.
The team of researchers from Henry Ford Hospital in Detroit analyzed the records of 990 patients with audiograms from 2000 to 2008. Patients were stratified by gender, age, diabetes and disorders.
Patients with diabetes were divided into two groups, namely well-controlled diabetes and poorly controlled. Groupings follow the guidelines of the American Diabetes Association.
Tim Henry Ford saw an average of measurements to determine the patient’s level of hearing at certain frequencies and the introduction of sound at different ages.
The team evaluated the average level of hearing that focused on the frequency of most people when talking and very high frequencies used in music and alarm.
Women aged 60-75 years of poorly controlled diabetes have a worse hearing than women whose diabetes is well controlled and compared to the control group.
Among women aged less than 60 years, diabetics have worse hearing than women without diabetes, regardless of diabetes is controlled or not.
While the men in this study found no significant difference in test results between men who develop diabetes well controlled, poorly controlled, and who do not have diabetes.
New Treatments for Diabetes
Type 2 diabetes, and chronic silent disease, Attacking without showing obvious symptoms are not yet diagnosed. New treatments coming to market. The “old” oral therapies (metformin and sulfonylureas) have limitations. They are effective at the beginning of type 2 diabetes, but insulin secretor failure of type 2 diabetes worsens over time, and several studies have shown a gradual increase almost inevitable in HbA1c, even in patients who come not to gain weight. A drug that can stop the insulin secretor failure would be welcome. Experiments in mice and some preliminary studies in humans had been led to expect that glitziness may have this property. The clinical experience shows that this is not the case
Rimonabant
Rimonabant (Acomplia) is a selective antagonist of type 1 to endocannabinoids. It is refunded if it is prescribed to patients with type 2 diabetes are overweight, when combined with metformin or sulphonylureas. The risk / benefit ratio of this treatment in terms of glucose lowering is not significant and it does not stop insulin secretors failure. It may be useful in diabetic patients with overweight is at the forefront, but the problem of continuing a very long time.
The in cretins
LPG-1 is an in cretin body’s natural. He was released early in the meal and acts on several levels: it inhibits the secretion of glucagon, it stimulates insulin secretion, it slows gastric emptying and have a central effect on satiety. But this natural hormone has a short half-life because it is distorted by a proteolysis enzyme called DPP-4. Two types of molecules have been developed: the analogs GPL-1 agonists that are resistant to the action of the enzyme and DPP-4 inhibitors that prolong the life LPG-1 Natural.
The Sitaggliptin has the same efficiency in terms of glucose as a sulfonamide less powerful, but it causes less hypoglycemia and less weight gain than this. However, this drug has side effects that lead to cautious use and no argument so far proves that the DPP-4 inhibitors do not inhibit the disappearance of cells to insulin. For these reasons, the combination metformin plus sulfonylurea classic always seems relevant.
Eventide is one of the alternatives to long-acting insulin at bedtime. It is probably less effective in terms of HbA1c as well titrated insulin at bedtime. But it leads to less weight gain and fixed-dose administered. However, it has some side effects of digestive and order is expensive (twice as expensive on average than insulin Glargine).